Parexel, a privately owned US company founded in 1982, is a large clinical research organization (CRO). Employing approximately 19,050 people, it offers a range of services to the pharmaceutical, biotechnology, and medical device industries globally. These services encompass contract research, consulting, medical communications, and technology solutions, spanning all phases of clinical drug development (Phase I-IV).
Parexel announced the appointment of Rob Goodwin as Chief Operating Officer (COO) in September 2025. Goodwin brings nearly 30 years of biopharmaceutical clinical development experience, most recently serving as Senior Vice President of Clinical Development and Operations at Pfizer. The appointment was also noted in a separate announcement.
Subscribe for full access to Parexel's products in full detail 
